ARTICLE | Clinical News
Dermagraft cryopreserved engineered human dermal substitute regulatory update
October 8, 2001 7:00 AM UTC
ATIS received U.S. marketing approval for its Dermagraft dermal replacement to treat chronic foot ulcers in diabetic patients, triggering a $5 million milestone from marketing partner Smith & Nephew ...